• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gain Therapeutics, Inc.

< Previous 1 2 Next >
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
July 16, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Proposed Public Offering
July 15, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
June 30, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate in Upcoming Investor Conferences
June 10, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
May 29, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
May 14, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
May 12, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
May 01, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
April 30, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
April 10, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
March 28, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
March 27, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
March 14, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
March 06, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
February 06, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Participate in Upcoming Investor Conferences
February 05, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
January 08, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
January 07, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
December 23, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Present At Biotech Showcase 2025
December 11, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
November 14, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
October 23, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 15, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
October 09, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
October 07, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at Upcoming Investor Conferences
October 03, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
September 30, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
September 26, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
September 19, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
< Previous 1 2 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap